Nimotuzumab in the treatment of solid tumors
10.3760/cma.j.issn.1673-422X.2013.12.010
- VernacularTitle:尼妥珠单抗治疗实体瘤的研究进展
- Author:
Qiaohong LIU
;
Linlin WANG
;
Yuping SUN
- Publication Type:Journal Article
- Keywords:
Receptor,epidermal growth factor;
Antibodies,monoclonal;
Neoplasms
- From:
Journal of International Oncology
2013;40(12):911-914
- CountryChina
- Language:Chinese
-
Abstract:
Nimotuzumab,a humanized monoclonal antibody against epidermal growth factor receptor (EGFR) can combine with extracellular domain of EGFR and inhibit downstream signaling pathways to prevent tumor growth.Clinical researches show that nimotuzumab has significant anti-tumor activity in several solid tumors such as squamous cell carcinoma of the head and neck,nasopharyngeal carcinoma,malignant glioma and so on,with advantages of good tolerance and low incidence of rashes.
